Significance of EGFR signaling pathway genetic alterations in radically resected non-small cell lung cancers from a Polish cohort. One institutional study

Cooper, 2013, Molecular biology of lung cancer, J Thorac Dis, 5, S479 Reungwetwattana, 2012, Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC), Clin Lung Cancer, 13, 252, 10.1016/j.cllc.2011.09.004 Cagle, 2012, Advances in treatment of lung cancer with targeted therapy, Arch Pathol Lab Med, 136, 504, 10.5858/arpa.2011-0618-RA Suda, 2014, Successes and limitations of targeted cancer therapy in lung cancer, Prog Tumor Res, 41, 62, 10.1159/000355902 Parums, 2014, Current status of targeted therapy in non-small cell lung cancer, Drugs Today (Barc), 50, 503, 10.1358/dot.2014.50.07.2185913 Dacic, 2011, Lung carcinoma morphology or mutational profile: that is the question, Arch Pathol Lab Med, 135, 1242, 10.5858/arpa.2011-0223-ED Swanton, 2009, Molecular classification of solid tumours: towards pathway-driven therapeutics, Br J Cancer, 100, 1517, 10.1038/sj.bjc.6605031 Moran, 2011, Importance of molecular features of non-small cell lung cancer for choice of treatment, Am J Pathol, 178, 1940, 10.1016/j.ajpath.2010.12.057 Kelloff, 2012, Cancer biomarkers: selecting the right drug for the right patient, Nat Rev Drug Discov, 11, 201, 10.1038/nrd3651 Sequist, 2011, Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice, Ann Oncol, 22, 2616, 10.1093/annonc/mdr489 Kowalczuk, 2014, CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes, Tumour Biol, 35, 4619, 10.1007/s13277-014-1605-x Schveigert, 2013, The value of MMP-9 for breast and non-small cell lung cancer patients’ survival, Adv Med Sci, 58, 73, 10.2478/v10039-012-0066-y Eberhard, 2008, Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting, J Clin Oncol, 26, 983, 10.1200/JCO.2007.12.9858 Carlson, 2009, Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis, J Cancer Res Clin Oncol, 135, 1483, 10.1007/s00432-009-0595-3 Brugger, 2011, Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer, J Clin Oncol, 29, 4113, 10.1200/JCO.2010.31.8162 Mao, 2010, KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies, Lung Cancer, 69, 272, 10.1016/j.lungcan.2009.11.020 Yamamoto, 2009, Impact of EGFR mutation analysis in non-small cell lung cancer, Lung Cancer, 63, 315, 10.1016/j.lungcan.2008.06.021 Dahabreh, 2011, EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer, Ann Oncol, 22, 545, 10.1093/annonc/mdq432 Wang, 2013, High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR, J Transl Med, 11, 90, 10.1186/1479-5876-11-90 Kim, 2008, Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung, Lung Cancer, 59, 111, 10.1016/j.lungcan.2007.08.008 Liu, 2010, Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan, J Thorac Oncol, 5, 1175, 10.1097/JTO.0b013e3181e2f4d6 Kosaka, 2009, Prognostic implication of EGFR, KRAS and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma, J Thorac Oncol, 4, 22, 10.1097/JTO.0b013e3181914111 Marks, 2008, Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma, J Thorac Oncol, 3, 111, 10.1097/JTO.0b013e318160c607 Sonobe, 2007, Influence of epidermal growth factor receptor (EGFR] gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer, J Surg Oncol, 95, 63, 10.1002/jso.20547 Liu, 2014, Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas, Med Oncol, 31, 771, 10.1007/s12032-013-0771-9 Goldstraw, 2007, The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours, J Thorac Oncol, 2, 706, 10.1097/JTO.0b013e31812f3c1a Chiosea, 2010, EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations, Hum Pathol, 41, 1053, 10.1016/j.humpath.2010.01.008 Szumera-Ciećkiewicz, 2013, EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and a systematic review of European incidence, Int J Clin Exp Pathol, 6, 2800 Koh, 2011, EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma, Jpn J Clin Oncol, 41, 548, 10.1093/jjco/hyq248 Hirsch, 2003, Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis, J Clin Oncol, 21, 3798, 10.1200/JCO.2003.11.069 Cappuzzo, 2009, Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients, J Clin Oncol, 27, 1667, 10.1200/JCO.2008.19.1635 Lee, 2013, EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and affect on response to EGFR-tyrosine kinase inhibitors in recurred cases, Ann Surg Oncol, 20, 3015, 10.1245/s10434-013-2937-2 Li, 2011, Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma, J Thorac Oncol, 6, 1016, 10.1097/JTO.0b013e318215a4f2 Takano, 2005, Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer, J Clin Oncol, 23, 6829, 10.1200/JCO.2005.01.0793 Bell, 2005, Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials, J Clin Oncol, 23, 8081, 10.1200/JCO.2005.02.7078 Beau-Faller, 2008, MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort, J Thorac Oncol, 3, 331, 10.1097/JTO.0b013e318168d9d4 Bonanno, 2010, Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcimoma, Anticancer Res, 30, 5121 Cappuzzo, 2005, Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients, J Clin Oncol, 23, 5007, 10.1200/JCO.2005.09.111 Chang, 2008, Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients, Lung Cancer, 61, 328, 10.1016/j.lungcan.2008.01.009 Varella-Garcia, 2009, EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort, J Thorac Oncol, 4, 318, 10.1097/JTO.0b013e31819667a3 Meert, 2005, Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC?, Lung Cancer, 47, 325, 10.1016/j.lungcan.2004.07.047 Yoshizawa, 2014, HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH], dual-ISH, and gene mutations, Lung Cancer, 85, 373, 10.1016/j.lungcan.2014.06.007 Wagner, 2011, Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma, Lung Cancer, 74, 118, 10.1016/j.lungcan.2011.01.029 Sasaki, 2011, Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer, J Thorac Oncol, 6, 15, 10.1097/JTO.0b013e31820594f0 Varella-Garcia, 2009, EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer, J Clin Pathol, 62, 970, 10.1136/jcp.2009.066548 Bohn-Hofstatter, 2010, Comparison of hybridization methods and real-time PCR: their value in animal cell line characterization, Appl Microbiol Biotechnol, 87, 419, 10.1007/s00253-010-2580-9 Grob, 2013, Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer, Lung Cancer, 79, 221, 10.1016/j.lungcan.2012.11.009 Gandhi, 2009, Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines, PLoS ONE, 4, e4576, 10.1371/journal.pone.0004576 Modrek, 2009, Oncogenic activating mutations are associated with local copy gain, Mol Cancer Res, 7, 1244, 10.1158/1541-7786.MCR-08-0532 Weir, 2007, Characterizing the cancer genome in lung adenocarcinoma, Nature, 450, 893, 10.1038/nature06358 Landi, 2013, HER2 and lung cancer, Expert Rev Anticancer Ther, 13, 1219, 10.1586/14737140.2013.846830 Onn, 2004, Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer, Clin Cancer Res, 10, 136, 10.1158/1078-0432.CCR-0373-3 Marchetti, 2011, Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations, J Clin Oncol, 29, 3574, 10.1200/JCO.2011.35.9638 Kobayashi, 2011, Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer, Anticancer Res, 31, 4619 Charkiewicz, 2013, New monoallelic combination of KRAS gene mutations in codons 12 and 13 in the lung adenocarcinoma, Adv Med Sci, 58, 83, 10.2478/v10039-012-0080-0 Riely, 2009, KRAS mutations in non-small cell lung cancer, Proc Am Thorac Soc, 6, 201, 10.1513/pats.200809-107LC Dacic, 2010, Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas, Mol Pathol, 23, 159, 10.1038/modpathol.2009.154 Krawczyk, 2015, The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study, J Cancer Res Clin Oncol, 141, 61, 10.1007/s00432-014-1789-x Tam, 2006, Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features, Clin Cancer Res, 12, 1647, 10.1158/1078-0432.CCR-05-1981 Bae, 2007, EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients, Cancer Genet Cytogenet, 173, 107, 10.1016/j.cancergencyto.2006.10.007 Lai, 2013, EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features, Int J Mol Sci, 14, 24549, 10.3390/ijms141224549 Soh, 2008, Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung, J Thorac Oncol, 3, 340, 10.1097/JTO.0b013e318168d20a Liang, 2010, Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas, BMC Cancer, 10, 376, 10.1186/1471-2407-10-376 Han, 2012, EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node metastasis, Cancer Lett, 314, 63, 10.1016/j.canlet.2011.09.012 Yoshida, 2005, Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung, Lung Cancer, 50, 1, 10.1016/j.lungcan.2005.04.012 Monaco, 2010, A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases, Hum Pathol, 41, 94, 10.1016/j.humpath.2009.06.019 Sun, 2011, Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice, J Exp Clin Cancer Res, 30, 30, 10.1186/1756-9966-30-30 Wang, 2014, Comparison of epidermal growth factor receptor mutations between primary tumors and lymph nodes in non-small cell lung cancer: a review and meta-analysis of published data, Asian Pac J Cancer Prev, 15, 4493, 10.7314/APJCP.2014.15.11.4493 Yatabe, 2008, Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer, Cancer Res, 68, 2106, 10.1158/0008-5472.CAN-07-5211 Soh, 2009, Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells, PLoS ONE, 4, e7464, 10.1371/journal.pone.0007464 Sholl, 2009, Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers, Cancer Res, 69, 8341, 10.1158/0008-5472.CAN-09-2477 Oakley, 2011, Higher dosage of the epidermal growth factor receptor mutant allele in lung adenocarcinoma correlates with younger age, stage IV at presentation, and poorer survival, J Thorac Oncol, 6, 1407, 10.1097/JTO.0b013e31821d41af Chiosea, 2011, KRAS mutant allele-specific imbalance in lung adenocarcinoma, Mol Pathol, 24, 1571, 10.1038/modpathol.2011.109 Hartman, 2012, Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival, Int J Cancer, 131, 1810, 10.1002/ijc.27461 Sonobe, 2012, Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas, Ann Surg Oncol, 3, S347, 10.1245/s10434-011-1799-8 Johnson, 2013, Association of KRAS and EFDR mutations with survival in patients with advanced lung adenocarcinomas, Cancer, 119, 356, 10.1002/cncr.27730 Zhao, 2011, The relationship between EGFR gain and VHL loss in lung adenocarcinoma and poor patient survival, Int J Clin Oncol, 16, 679, 10.1007/s10147-011-0248-9 Sasaki, 2009, Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer, Lung Cancer, 64, 295, 10.1016/j.lungcan.2008.10.005 Tan, 2003, HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization, Diagn Mol Pathol, 12, 201, 10.1097/00019606-200312000-00004 López-Malpartida, 2009, Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas, Lung Cancer, 65, 25, 10.1016/j.lungcan.2008.10.009 Woo, 2009, Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas, Lung Cancer, 65, 355, 10.1016/j.lungcan.2008.11.020 Meng, 2013, Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis, Lung Cancer, 81, 1, 10.1016/j.lungcan.2013.03.019